| scholarly article | Q13442814 |
| P50 | author | Aurora S Blucher | Q89111566 |
| P2093 | author name string | Guanming Wu | |
| Shannon McWeeney | |||
| Molly Kulesz-Martin | |||
| Lynne Shinto | |||
| Gabrielle Choonoo | |||
| Steven R Chamberlin | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| KEGG: kyoto encyclopedia of genes and genomes | Q24515297 | ||
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| A Comparative Analysis of Community Detection Algorithms on Artificial Networks | Q26779592 | ||
| The Chemical Translation Service--a web-based tool to improve standardization of metabolomic reports | Q27062596 | ||
| A comparative study of cancer proteins in the human protein-protein interaction network | Q27496590 | ||
| The BioGRID interaction database: 2015 update | Q28252221 | ||
| Network pharmacology: the next paradigm in drug discovery | Q28297997 | ||
| Use of natural products as chemical library for drug discovery and network pharmacology | Q28487019 | ||
| AfroDb: a select highly potent and diverse natural product library from African medicinal plants | Q28534724 | ||
| Synergistic and antagonistic drug combinations depend on network topology | Q28542101 | ||
| TarNet: An Evidence-Based Database for Natural Medicine Research | Q28552085 | ||
| BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology | Q28603124 | ||
| Drug-target network | Q29614447 | ||
| Global mapping of pharmacological space | Q29615876 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| A human functional protein interaction network and its application to cancer data analysis | Q33581341 | ||
| Network systems biology for drug discovery | Q33592795 | ||
| The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression | Q33695077 | ||
| Network target for screening synergistic drug combinations with application to traditional Chinese medicine | Q33937467 | ||
| Mining the metabiome: identifying novel natural products from microbial communities | Q34228002 | ||
| Combinatorial drug therapy for cancer in the post-genomic era. | Q34287101 | ||
| Drug resistance in cancer: an overview. | Q34437369 | ||
| The re-emergence of natural products for drug discovery in the genomics era. | Q34459318 | ||
| Topology of molecular interaction networks | Q34508185 | ||
| Natural Products as Sources of New Drugs from 1981 to 2014. | Q34512692 | ||
| Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. | Q52806460 | ||
| Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer. | Q53760450 | ||
| Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs | Q59799448 | ||
| Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network | Q81378507 | ||
| Mechanisms of drug combinations: interaction and network perspectives | Q83265745 | ||
| Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy | Q89406920 | ||
| Phorbol esters: structure, biological activity, and toxicity in animals. | Q34657244 | ||
| Using graph theory to analyze biological networks | Q35005792 | ||
| Do cancer proteins really interact strongly in the human protein-protein interaction network? | Q35034277 | ||
| The Reactome pathway Knowledgebase | Q35866115 | ||
| The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer | Q36093876 | ||
| Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer. | Q36139333 | ||
| A map of human cancer signaling | Q36327214 | ||
| A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. | Q36396515 | ||
| TCMID: Traditional Chinese Medicine integrative database for herb molecular mechanism analysis | Q36491360 | ||
| Getting connected: analysis and principles of biological networks | Q36808436 | ||
| Therapeutic target database update 2014: a resource for targeted therapeutics | Q37661746 | ||
| Exploring compound promiscuity patterns and multi-target activity spaces | Q38201052 | ||
| Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model | Q38725199 | ||
| Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo. | Q38854749 | ||
| Phytomedicine-Modulating oxidative stress and the tumor microenvironment for cancer therapy | Q38994318 | ||
| Predicting synergistic effects between compounds through their structural similarity and effects on transcriptomes | Q39474699 | ||
| Patient compliance with cervical smear surveillance in a shared-care setting. | Q39566432 | ||
| Evidence-Based and Quantitative Prioritization of Tool Compounds in Phenotypic Drug Discovery | Q39592577 | ||
| Perspectives on the development of imatinib and the future of cancer research | Q39940683 | ||
| Synergy evaluation by a pathway-pathway interaction network: a new way to predict drug combination | Q40188819 | ||
| DrugComboRanker: drug combination discovery based on target network analysis | Q40749664 | ||
| Construction of human activity-based phosphorylation networks. | Q40836487 | ||
| Utility of network integrity methods in therapeutic target identification | Q41829537 | ||
| High-resolution view of compound promiscuity | Q42090248 | ||
| Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery | Q46260661 | ||
| Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol | Q46278768 | ||
| The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. | Q47139831 | ||
| Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy | Q47303076 | ||
| Evidence-Based Precision Oncology with the Cancer Targetome. | Q47893147 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | Cytoscape | Q3699942 |
| P921 | main subject | natural product | Q901227 |
| P304 | page(s) | 557 | |
| P577 | publication date | 2019-05-31 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Natural Product Target Network Reveals Potential for Cancer Combination Therapies | |
| P478 | volume | 10 |
| Q89834779 | 2α-Hydroxyeudesma-4,11(13)-Dien-8β,12-Olide Isolated from Inula britannica Induces Apoptosis in Diffuse Large B-cell Lymphoma Cells |
| Q92630031 | Chelerythrine Chloride Downregulates β-Catenin and Inhibits Stem Cell Properties of Non-Small Cell Lung Carcinoma |
| Q92153398 | Multifloroside Suppressing Proliferation and Colony Formation, Inducing S Cell Cycle Arrest, ROS Production, and Increasing MMP in Human Epidermoid Carcinoma Cell Lines A431 |
Search more.